Authors

Qian Zhao, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine
Shengqiong Deng, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine
Guangxue Wang, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine
Cuicui Liu, Shanghai East Hospital, Dalian Medical University
Lingyu Meng, Shanghai East Hospital, Dalian Medical University
Shanshan Qiao, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine
Lei Shen, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine
Yue Zhang, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine
Jinhui Lü, School of Basic Medical Sciences, Wenzhou Medical University
Yuzhen Zhang, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine
Min Wang, Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson UniversityFollow
Richard Pestell, Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson UniversityFollow
Chunli Liang, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine
Zuoren Yu, Research Center for Translational Medicine, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine; Shanghai East Hospital, Dalian Medical University; School of Basic Medical Sciences, Wenzhou Medical University
Wenshu Li, School of Basic Medical Sciences, Wenzhou Medical University

Document Type

Article

Publication Date

4-19-2016

Comments

This article has been peer reviewed. It was published in: Oncotarget.

Volume 7, Issue 16, 19 April 2016, Pages 21865-21874.

The published version is available at DOI: 10.18632/oncotarget.7990

Copyright © 2016 The Authors

Abstract

Circulating miRNAs are protected from ribonuclease degradation by assembly into microvesicles and exosomes. Releasing miRNAs completely from these particles is the key step to quantify the circulating miRNAs. Currently purified RNA-based quantitative analysis is widely used while it is time and cost consuming with high risk for those circulating miRNAs with low abundance due to partial loss of RNA during the steps of total RNA extraction and small RNA enrichment. Herein, we optimized a simple, effective and time-saving method to directly measure plasma miRNAs without RNA isolation. It is based on complete miRNA release from the protein complexes, followed by miRNA-specific reverse transcription and quantitative real-time PCR amplification. By comparison to the RNA-based approach, the direct quantification method showed more efficiency for circulating miRNA analysis, higher accuracy and specificity. By application of the direct quantification method to clinical samples combined with the RNA-based miRNA screening analysis, upregulation of miR-106a in blood was validated in metastatic breast cancer patients, indicating miR-106a are a potential biomarker for metastatic breast cancer.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Included in

Oncology Commons

Share

COinS